To deepen the value of inclusion and empathy in corporate culture, PatientsForce has launched a deep collaboration with the Rare Disease Foundation (TFRD), jointly promoting the life education program “Rare Disease Professionals Enter Companies and Civil Organizations.” Recently, this project successfully brought this warmth and inspiration to Takeda Taiwan, inviting rare disease artisan Yaqi to give in-depth talks and share essential oil crafts with corporate colleagues. We hope that by substantively connecting industry and social disadvantaged groups, companies can see the challenges, fearless resilience, and love of life behind families with rare diseases.

Taiwan’s National Health Insurance system has long been widely recognized internationally, with public satisfaction consistently at a high level. However, with advances in medical technology and changes in disease patterns, modern healthcare has gradually extended from “treatment itself” to “management and support throughout the treatment process.”

Recently, the Asia-Pacific Regional Situation Monthly Monthly published by the Pacific Economic Cooperation Council Council (CTPECC) featured an exclusive interview with PatientsForce COO Wang Yiwen. An in-depth exploration of how, in a complex institutional environment, companies can leverage digital platforms and service innovation to build comprehensive and inclusive health management systems.

There are about 7,000 known rare diseases worldwide, of which approximately 80% are hereditary; However, only about a few hundred rare diseases can be treated with medication, accounting for roughly 5% of all rare diseases. For most patients, the real challenge is not simply not necessarily having the medication, but that even when the medication is available, they often get stuck at the three hurdles of “not waiting, unable to afford, and unable to renew.”

The Patient Support Program (PSP) market has grown rapidly in Taiwan over the past few years. But if we look back from 2026, we see that the very nature of PSPs has fundamentally changed. It is no longer just a “patient care service”, nor is it just a medication reminder, health education tracking, or customer service mechanism, but a key watershed moment in the era of value-based care.

The Patient Support Program (PSP) market has grown rapidly in Taiwan over the past few years. But if we look back from 2026, we see that the very nature of PSPs has fundamentally changed. It is no longer just a “patient care service”, nor is it just a medication reminder, health education tracking, or customer service mechanism, but a key watershed moment in the era of value-based care.

The Patient Support Program (PSP) market has grown rapidly in Taiwan over the past few years. But if we look back from 2026, we see that the very nature of PSPs has fundamentally changed. It is no longer just a “patient care service”, nor is it just a medication reminder, health education tracking, or customer service mechanism, but a key watershed moment in the era of value-based care.